Lupin Limited has entered into a licensing and supply agreement with Zydus Lifesciences Limited to co-market an innovative semaglutide injection in India, aimed at expanding access to advanced therapies for diabetes and weight management.

Under the agreement, Lupin will have semi-exclusive rights to market the product in India under the brands Semanext and Livarise, while Zydus will continue to sell it under its existing brands. The partnership combines Lupin’s strong domestic reach with Zydus’ development capabilities.

As part of the deal, Lupin will pay upfront licensing fees along with milestone-based payments tied to predefined targets.

Semaglutide is used for the treatment of type 2 diabetes as well as for chronic weight management in adults, alongside diet and exercise. The product features a patient-friendly reusable pen device designed to improve ease of use and adherence.

The companies said the collaboration aims to enhance access to innovative treatment options for cardio-metabolic diseases and address growing patient needs across India.